We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
- Authors
Zablotska, Iryna B.; Selvey, Christine; Guy, Rebecca; Price, Karen; Holden, Jo; Schmidt, Heather-Marie; McNulty, Anna; Smith, David; Jin, Fengyi; Amin, Janaki; Cooper, David A.; Grulich, Andrew E.; on behalf of the EPIC-NSW study group; EPIC-NSW study group
- Abstract
<bold>Background: </bold>The New South Wales (NSW) HIV Strategy 2016-2020 aims for the virtual elimination of HIV transmission in NSW, Australia, by 2020. Despite high and increasing levels of HIV testing and treatment since 2012, the annual number of HIV diagnoses in NSW has remained generally unchanged. Pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV infection among gay and bisexual men (GBM) when taken appropriately. However, there have been no population-level studies that evaluate the impact of rapid PrEP scale-up in high-risk GBM. Expanded PrEP Implementation in Communities in NSW (EPIC-NSW) is a population-level evaluation of the rapid, targeted roll-out of PrEP to high-risk individuals.<bold>Methods: </bold>EPIC-NSW, is an open-label, single-arm, multi-centre prospective observational study of PrEP implementation and impact. Over 20 public and private clinics across urban and regional areas in NSW have participated in the rapid roll-out of PrEP, supported by strong community mobilization and PrEP promotion. The study began on 1 March 2016, aiming to enroll at least 3700 HIV negative people at high risk of HIV. This estimate took into consideration criteria for PrEP prescription in people at high risk for acquiring HIV as defined in the NSW PrEP guidelines. Study participants receive once daily co-formulated tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) and are followed for up to 24 months. Follow-up includes: testing for HIV at 1 month, HIV and other sexually transmissible infections three-monthly, HCV annually and monitoring of renal function six-monthly. Optional online behavioural surveys are conducted quarterly. The co-primary endpoints are (i) HIV diagnoses and incidence in the cohort and (ii) HIV diagnoses in NSW.<bold>Discussion: </bold>EPIC-NSW is a population-based PrEP implementation trial which targets the entire estimated population of GBM at high risk for HIV infection in NSW. It will provide a unique opportunity to evaluate the population impact of PrEP on a concentrated HIV epidemic.<bold>Trial Registration: </bold>https://clinicaltrials.gov/ (identifying number NCT02870790 ; registration date 14 August 2016), pre-results stage.
- Subjects
NEW South Wales; HIV infection risk factors; MEN who have sex with men; PREVENTIVE medicine; ANTIRETROVIRAL agents; HEALTH outcome assessment; HEALTH; DIAGNOSIS of HIV infections; HIV prevention; ANTI-HIV agents; HIV infection epidemiology; BISEXUALITY; COMMUNITY health services administration; COMPARATIVE studies; DRUGS; EXPERIMENTAL design; HOMOSEXUALITY; LONGITUDINAL method; RESEARCH methodology; MEDICAL care research; MEDICAL cooperation; PATIENT compliance; PREVENTIVE health services; RESEARCH; RISK assessment; EVALUATION research
- Publication
BMC Public Health, 2018, Vol 18, p1
- ISSN
1471-2458
- Publication type
journal article
- DOI
10.1186/s12889-017-5018-9